Brief: Shanghai Junshi Biosciences Says Toripalimab Met Primary Endpoint
26/05/2026 16:24
BRIEF-Shanghai Junshi Biosciences Says Toripalimab Met Primary Endpoint May 26 (Reuters) - Shanghai Junshi Biosciences Co Ltd 688180.SS:
TORIPALIMAB AS PERIOPERATIVE TREATMENT FOR RESECTABLE STAGE II-III NSCLC- PATIENTS MET PRIMARY ENDPOINT
TORIPALIMAB MET PRIMARY ENDPOINT IN FINAL ANALYSIS OF PHASE III CLINICAL STUDY
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab